1st ProCAncer-I Project Dissemination Event in Vienna

An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility. 

Welcome by Coordinating Team

We are very glad to lead a very ambitious and health-driven project that could end to alleviating and helping thousands of men to tackle prostate cancer in a more personalized way supporting a better quality of life

The Coordinating Team

Manolis Tsiknakis

Prof. Manolis Tsiknakis
(Coordinator)

Dr. Nikolaos Papanikolaou
(Scientific Manager)

Prof. Kostas Marias
(Technical Manager)

Prof. Daniele Regge
(Clinical Manager)

The ProCAncer-I project is one of the founding projects of the FUTURE-AI.

FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation, and deployment of trustworthy AI solutions in medical imaging based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness, and Explainability.

Project Information

Months (Duration)

Euros (Total Budget )

Grant Agreement Nr.

Funded

This project has received funding from the European Union’s Horizon 2020 research and innovation programme

|

Topic

DT-TDS-05-2020:
AI for Health Imaging

Highlights

5th Consortium Meeting in Turin

5th Consortium Meeting in Turin

The 5th ProCAncer-I Consortium Meeting took place on the 07 – 08 November 2022, at ILO Campus, in Turin. The meeting was hybrid and more than 65 people attended the meeting. This was the first physical meeting where almost all partners were present, and we were glad...

ProCAncer-I at the National Congress TURKRAD 2022 in Antalya

ProCAncer-I at the National Congress TURKRAD 2022 in Antalya

Our partner Hacettepe University, School of Medicine, Department of Radiology (HACETTEPE) participated at the 43rd Turkish National Radiology Congress(TURKRAD 2022)  in Antalya(02-06/11/2022).  Prof. Deniz Akata presented ProCAncer – I project, the aim and its...

Dr Nickolas Papanikolaou our Scientific Manager, will be at the #RSNA22 with a session this Sunday. The panel will include Dr Mona Flores and Dr Rowland Illing, discussing the role of Academia and Industry in bringing #AI innovations in #radiology

The #ProCAncer_I participated in the Clinical and Translational Oncology Conference 2022 in Heraklion. The latest developments in #Oncology were presented, with a special view on the innovations being introduced into clinical medical practice👉https://bit.ly/3ABmXla
#H2020 #AI

4

#Movember is an initiative to raise awareness for #prostate cancer and other male diseases. It takes place all November, every year. Spread the word!
#Movember2022 #ProCAncerI #prostatecancer #menshealth #movember

Load More...

Stay in touch!